Displaying drugs 14676 - 14700 of 15703 in total
Stannsoporfin
Stannsoporfin is a competitive heme oxygenase (HO) inhibitor being developed by InfaCare, a subsidiary of WellSpring Pharmaceuticals, for the prevention of hyperbilirubinemia in infants at risk of developing jaundice.
Investigational
INCB13739
INCB13739 is developed as a new treatment for type 2 diabetes.
It is an orally available small molecule inhibitor of 11beta-HSD1 (11-beta hydroxysteroid dehydrogenase type 1). 11beta-HSD1 is an enzyme that appears to be critical to the development of type 2 diabetes.
Investigational
MN-305
MN-305 is a novel, potent and highly selective serotonin 5-HT1A receptor agonist under development by MediciNova for the treatment of anxiety disorders beginning with Generalized Anxiety Disorder (GAD).
Investigational
Matched Description: … MN-305 is a novel, potent and highly selective serotonin 5-HT1A receptor agonist under development by …
Biomed 101
Biomed 101 is investigated for use/treatment in adverse effects (chemotherapy) and renal cell carcinoma. Biomed 101 is a solid. Biomed 101 binds to the leukotriene B4 receptor, but does not affect interleukin-2 antitumor activity.
Investigational
Matched Description: … Biomed 101 is investigated for use/treatment in adverse effects (chemotherapy) and renal cell carcinoma …
Mirostipen
Investigational
Amperozide
Amperozide is a diphenylbutylpiperazine atypical antipsychotic which antagonizes 5-HT2A receptors. It inhibits dopamine release and alters the firing of dopaminergic neurons. Investigations regarding the use of the agent revolved primarily around its capability for treating schizophrenia in humans even though the drug was ultimately never clinically adopted for this indication....
Experimental
Matched Description: … It inhibits dopamine release and alters the firing of dopaminergic neurons. ... amperozide's main use lies in veterinary medicine, where it is typically employed to minimize aggression and …
Eprenetapopt
Eprenetapopt has been used in trials studying the treatment of Prostatic Neoplasms, Hematologic Neoplasms, and Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53.
Investigational
Matched Description: … Eprenetapopt has been used in trials studying the treatment of Prostatic Neoplasms, Hematologic Neoplasms, and …
BMS-986012
BMS-986012 is a human antifucosyl-GM1 antibody. It is under investigation in clinical trial NCT02815592 (Trial of BMS-986012 in Combination With Platinum and Etoposide).
Investigational
Matched Description: … under investigation in clinical trial NCT02815592 (Trial of BMS-986012 in Combination With Platinum and …
Semorinemab
Semorinemab is under investigation in clinical trial NCT03289143 (A Study to Evaluate the Efficacy and Safety of RO7105705 in Patients With Prodromal to Mild Alzheimer's Disease).
Investigational
Matched Description: … Semorinemab is under investigation in clinical trial NCT03289143 (A Study to Evaluate the Efficacy and …
Reldesemtiv
Reldesemtiv is under investigation in clinical trial NCT03160898 (A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)).
Investigational
Matched Description: … Reldesemtiv is under investigation in clinical trial NCT03160898 (A Study to Evaluate Efficacy, Safety and …
Bintrafusp alfa
Bintrafusp alfa is under investigation in clinical trial NCT03833661 (M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)).
Investigational
Matched Description: … Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and …
Ispronicline
Ispronicline is under investigation in clinical trial NCT00109564 (A Safety and Efficacy Study of Ispronicline (TC-1734-112) in Subjects With Age Associated Memory Impairment (AAMI)).
Investigational
Matched Description: … Ispronicline is under investigation in clinical trial NCT00109564 (A Safety and Efficacy Study of Ispronicline …
Opiranserin
Opiranserin is under investigation in clinical trial NCT03997838 (Evaluate the Efficacy and Safety of VVZ-149 Injections for the Treatment of Post-operative Pain Following Abdominoplasty).
Investigational
Matched Description: … Opiranserin is under investigation in clinical trial NCT03997838 (Evaluate the Efficacy and Safety of …
AGT-182
AGT-182 is an investigational enzyme replacement therapy engineered by the fusion of the iduronate-2-sulfatase (IDS) enzyme and a human insulin receptor monoclonal antibody.
Investigational
Matched Description: … investigational enzyme replacement therapy engineered by the fusion of the iduronate-2-sulfatase (IDS) enzyme and …
TORL-2-307
TORL-2307 is a humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) directed against claudin 18.2 (CLDN18.2) being investigated for the treatment of gastric and pancreatic cancer.
Investigational
Matched Description: … antibody (mAb) directed against claudin 18.2 (CLDN18.2) being investigated for the treatment of gastric and …
Tidutamab
Tidutamab is under investigation in clinical trial NCT04590781 (Safety and Efficacy of Xmab18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer).
Investigational
Matched Description: … Tidutamab is under investigation in clinical trial NCT04590781 (Safety and Efficacy of Xmab18087 ± Pembrolizumab …
Tobemstomig
Tobemstomig is under investigation in clinical trial NCT05908786 (A Study Evaluating the Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma).
Investigational
Matched Description: … Tobemstomig is under investigation in clinical trial NCT05908786 (A Study Evaluating the Efficacy and …
NP-50301
NP-50301 is an ophthalmic therapeutic eye drop treating post-menopausal Dry Eye Syndrome (DES). It is being developed by Nascent Pharmaceuticals. It is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over 12 million women in the U.S. The majority of sufferers of DES are...
Investigational
Matched Description: … The majority of sufferers of DES are postmenopausal women; and clinical research around the world has ... suggested the benefits of both topical and systemic estrogen therapy in the treatment of DES in this …
MPI-674
MPI-674 is an aromatase inhibitor (AI) with a well-established, multi-year chronic safety and tolerability profile. AIs are a class of drugs that reduce the amount of estrogen circulating in the body by binding to and inhibiting the enzyme aromatase, which is responsible for converting certain hormones to estrogen. It is...
Investigational
Matched Description: … MPI-674 is an aromatase inhibitor (AI) with a well-established, multi-year chronic safety and tolerability ... AIs are a class of drugs that reduce the amount of estrogen circulating in the body by binding to and …
AT1391
AT1391 is a daily insulin skin patch designed to provide continuous basal levels of insulin for patients with diabetes.
Investigational
WL-1002
WL-1002 is developed by Winston Laboratories which is a topical cream formulation of 075% zucapaicin (also known as civamide), for the treatment of pain due to osteoarthritis.
Investigational
Actelion-1
Actelion-1 is a tissue-targeting Endothelin Receptor Antagonist that has been discovered by Actelion Pharmaceuticals.
Investigational
13-deoxydoxorubicin
GPX-100 is an anthracycline anticancer drug that belongs to the family of drugs called antitumor antibiotics.
Investigational
ABX-PTH
ABX-PTH is a fully human monoclonal antibody generated by Abgenix's technology platform. This drug targets and neutralizes the action of parathyroid hormone (PTH) for the treatment of a secondary hyperparathyroidism.
Investigational
Matched Description: … This drug targets and neutralizes the action of parathyroid hormone (PTH) for the treatment of a secondary …
Linsitinib
An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. IGF-1R inhibitor OSI-906 selectively inhibits IGF-1R, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis.
Investigational
Matched Description: … OSI-906 selectively inhibits IGF-1R, which may result in the inhibition of tumor cell proliferation and …
Displaying drugs 14676 - 14700 of 15703 in total